Cargando…

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6

BACKGROUND: In the Phase III LUX-Lung 3/6 (LL3/LL6) trials in epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma patients, we evaluated feasibility of EGFR mutation detection using circulating cell-free DNA (cfDNA) and prognostic and predictive utility of cfDNA positivity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Yi-Long, Sequist, Lecia V, Hu, Cheng-Ping, Feng, Jifeng, Lu, Shun, Huang, Yunchao, Li, Wei, Hou, Mei, Schuler, Martin, Mok, Tony, Yamamoto, Nobuyuki, O'Byrne, Kenneth, Hirsh, Vera, Gibson, Neil, Massey, Dan, Kim, Miyoung, Yang, James Chih-Hsin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5243999/ https://www.ncbi.nlm.nih.gov/pubmed/28006816 http://dx.doi.org/10.1038/bjc.2016.420

Ejemplares similares

Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)
por: Wu, Yi-Long, et al.
Publicado: (2017)

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
por: Schuler, Martin, et al.
Publicado: (2019)

Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2019)

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
por: Paz-Ares, L., et al.
Publicado: (2017)

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3
por: Kato, Terufumi, et al.
Publicado: (2015)

Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
por: Digumarthy, Subba R., et al.
Publicado: (2019)

Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial
por: Wu, Yi-Long, et al.
Publicado: (2018)

Revolving Door of Histologic Transformation—Tumor Heterogeneity Complicating the Management of EGFR-Mutated Lung Adenocarcinoma: A Case of Jekyll and Hyde
por: Wysota, Michael, et al.
Publicado: (2020)

Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status?
por: Digumarthy, Subba R., et al.
Publicado: (2019)

Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors
por: Hirsh, Vera
Publicado: (2018)

Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity
por: Marcar, Lynnette, et al.
Publicado: (2019)

Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs
por: Melosky, Barbara, et al.
Publicado: (2014)

Germline mutations and developmental mosaicism underlying EGFR-mutant lung cancer
por: Burr, Risa, et al.
Publicado: (2023)

Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2018)

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
por: Niederst, Matthew J., et al.
Publicado: (2015)

Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program
por: Tu, Hai-Yan, et al.
Publicado: (2020)

Lux Aeterna
por: Mathias, William
Publicado: (1989)

Optimal sequencing strategies in the treatment of EGFR mutation–positive non–small cell lung cancer: Clinical benefits and cost-effectiveness
por: Hirsh, Vera, et al.
Publicado: (2020)

Microbial Primer: LuxR-LuxI Quorum Sensing
por: Soto-Aceves, Martin P., et al.
Publicado: (2023)

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
por: O’Leary, Connor, et al.
Publicado: (2020)

Bone matters in lung cancer
por: Brodowicz, T., et al.
Publicado: (2012)

Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program
por: Santos, Edgardo S., et al.
Publicado: (2018)

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
por: Chabon, Jacob J., et al.
Publicado: (2016)

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
por: Raoof, Sana, et al.
Publicado: (2019)

Genetic Associations of Visfatin Polymorphisms with EGFR Status and Clinicopathologic Characteristics in Lung Adenocarcinoma
por: Chang, Sunny Li-Yun, et al.
Publicado: (2022)

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
por: Schuler, M., et al.
Publicado: (2016)

Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
por: Chabon, Jacob J., et al.
Publicado: (2016)

Genomic characterization of bacteria from the ultra-oligotrophic Madison aquifer: insight into the archetypical LuxI/LuxR and identification of novel LuxR solos
por: Wengert, Peter C., et al.
Publicado: (2021)

Census of solo LuxR genes in prokaryotic genomes
por: Hudaiberdiev, Sanjarbek, et al.
Publicado: (2015)

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial
por: Goss, Glenwood D, et al.
Publicado: (2021)

Une physique de luxe
Publicado: (1983)

LuxS and quorum-sensing in Campylobacter
por: Plummer, Paul J.
Publicado: (2012)

Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis
por: Paz-Ares, Luis, et al.
Publicado: (2010)

Long-term survival in a patient with advanced non-smoking lung adenocarcinoma and no EGFR mutation after comprehensive therapy with EGFR-TKI-based therapy: A case report
por: Zhang, Qianyu, et al.
Publicado: (2022)

Incidence of Radiation Therapy Among Patients Enrolled in a Multidisciplinary Pulmonary Nodule and Lung Cancer Screening Clinic
por: Milligan, Michael G., et al.
Publicado: (2022)

Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor‐Mutant Lung Cancer
por: Fintelmann, Florian J., et al.
Publicado: (2019)

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report
por: Yang, James Chih-Hsin, et al.
Publicado: (2022)

OPAL: Physiciens dans l'UX
Publicado: (1992)

LuxR solos in Photorhabdus species
por: Brameyer, Sophie, et al.
Publicado: (2014)

Fiat Lux: illuminating the cell cycle
por: Liccardi, Gianmaria, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_unr2bgrtlbissor0dldnro3q1o